Yahoo Finance Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea (OSA), a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep.
The data showed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies.
AHI records the number of times a person’s breathing shows a restricted or complete block of airflow per hour of sleep.
SURMOUNT-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on positive airway pressure (PAP) therapy for 52 weeks.
Tirzepatide injection led to a mean AHI reduction of 27.4 events per hour from baseline compared to a mean AHI reduction of 4.8 events per hour for placebo.
In key secondary outcomes, Tirzepatide led to a mean AHI reduction from baseline of 55.0% compared to 5.0% from baseline for placebo.
Tirzepatide also led to a mean body weight reduction of 18.1% from baseline, compared to 1.3% from baseline for placebo.
SURMOUNT-OSA Study 2 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were on and planned to continue to use PAP therapy for 52 weeks.
In this population, at 52 weeks, tirzepatide led to a mean AHI reduction from baseline of 30.4 events per hour compared to a mean AHI reduction from baseline of 6.0 events per hour for the placebo.
In key secondary outcomes, tirzepatide led to a mean AHI reduction from baseline of 62.8% compared to 6.4% from baseline for placebo.
Tirzepatide also led to a mean body weight reduction of 20.1% from baseline, compared to 2.3% from baseline for placebo.
The weight loss observed at 52 weeks with tirzepatide (10 mg and 15 mg) across the two studies was nearly 20%.
Lilly plans to submit to the FDA and other global regulatory agencies beginning mid-year.
Price Action: LLY shares are up 2.58% at $766 during the premarket session on the last check Wednesday.
Photo via Wikimeida Commons
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
